Patent Grant
11504424
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 4, 2021, is named 17262263_Sequence_Listing.txt and is 140,297 bytes in size.
The present invention relates to virus strains genetically modified from a new human metapneumovirus strain.
The present invention relates to these modified strains, of which the virulence is attenuated, for the use thereof in the prophylactic or therapeutic treatment of infections with viruses of the Pneumoviridae family, as well as vaccine compositions comprising said modified virus strains.
Acute infections of the lower respiratory tracts are one of the major causes of morbidity and mortality on the global scale. In children less than 5 years old in particular, they represent up to more than 15% of mortality, depending on the countries evaluated, and are thus the second cause of mortality according to the World Health Organisation.
The majority of acute infections of the lower respiratory tracts, associated with variable pathologies ranging from a simple cold to serious pneumonia, are notably caused by viruses, such as those belonging to the following families:
The human syncytial respiratory virus (hRSV) and the human metapneumovirus (hMPV) are viruses responsible for acute infections of the respiratory tracts such as bronchiolitis, bronchitis or pneumonias. They mainly affect populations at risk, which are young children less than 5 years old, the elderly and immuno-depressed persons.
The hRSV is the main etiological agent of bronchiolitis and pneumonias in infants less than 1 year old, with an increased incidence below 6 months old. In adults, infection with hRSV is rare and benign, expect in elderly subjects. Transmission essentially takes place by respiratory route, the virus replicating in the respiratory tract.
The hRSV was isolated in 1957. It is a virus with single-stranded RNA of negative polarity, of “enveloped” type, with helical symmetry capsid. It belongs to the family Pneumoviridae and to the genus Orthopneumovirus.
The hMPV is prevalent in bronchiolitis and pneumonias in infants, and particularly severely affects children between 1 and 3 years old.
The main symptoms of infection by hMPV in children comprise rhinorrhoea, coughing, respiratory distress or instead fever. hMPV may also cause infections of the upper respiratory tracts, being able to be associated with ear infections, whereas non-respiratory symptoms, such as diarrhoea, vomiting and the occurrence of erythema, are rarer. hMPV preferentially targets the ciliated cells of the human respiratory tree.
An infection by hMPV induces histo-pathological modifications in the lungs of the host organism, and generates in particular the following physiological effects:
In respiratory pathologies in adults, hMPV has been identified in 5 to 10% of adults or older persons having an acute infection of the respiratory tracts, and in 3 to 5% of adults having an exacerbation of a chronic pulmonary pathology or a pneumonia acquired in community.
The hMPV was isolated and described for the first time in 2001 in the Netherlands (van den Hoogen et al., 2001). The following year, several strains of hMPV were isolated in patients located in North America (Peret et al., 2002). hMPV are viruses with negative single-stranded RNA, belonging to the family Pneumoviridae and to the genus Metapneumovirus.
The average age of children hospitalised due to complications of an infection by hMPV is 6 to 12 months, i.e. later than that caused by hRSV, which mainly occurs between 0 and 3 months. However, the epidemiology of hMPV has numerous common points with that of hRSV:
No prophylactic or therapeutic modality that is efficient and specific against infection by the viruses hRSV and hMPV exists today on the market, although active research is underway (Mazur et al., 2018).
For treatment, ribavirin, not exempt from undesirable effects, or intravenous immunoglobulins, very expensive, may be used occasionally in serious cases of infections by hMPV or hRSV.
Other types of treatments are currently being developed such as the use of fusion inhibitor peptides, sulphated glycosaminoglycans, interfering RNAs and certain immunomodulators.
The usual and widely favoured clinical approach today consists in treating especially the symptoms of the infection, while placing patients under respiratory assistance (administration of oxygen or mechanical ventilation) and by administering to them bronchodilators, corticosteroids and/or antibiotics for preventing or treating bacterial superinfections.
Regarding the vaccination, the populations particularly affected by hMPV being infants, young children and the elderly, it is crucial to have rapidly safe and effective vaccines, in order to reduce severe respiratory attacks which have a dramatic impact in these age ranges.
The development of a vaccine against hRSV and hMPV thus represents not only a major health challenge, but also a real socio-economic issue with the objective of reducing the high cost of treatments and hospitalisations associated with these infections, and of decreasing the use of antibiotics in the context of bacterial superinfections, and thus limiting the emergence of resistances.
Tables 1, 2 and 3 below list the different approaches under development for obtaining living attenuated vaccines from wild hMPV strains.
Virus strains are considered as being attenuated in vitro when they exhibit decreased replicative capacity compared to the wild type (WT) virus, and/or when these virus strains lead to the more restricted formation of infectious outbreaks, notably of syncytia (adjacent cells fusing following viral infection). In vivo, attenuated virus strains replicate at a lower maximum load and/or induce less severe pathology (in terms of weight loss or inflammatory profile or histo-pathological damage) than the wild virus strain.
The following abbreviations are used for the in vivo study models: M for Mouse; H for Hamster; CR for Cotton Rat; CM for Cynomolgus Macaque; AGM for African Green Monkey; Ch for Chimpanzee; Rh for Rhesus Monkey; and SCID for Severe Combined ImmunoDeficiency.
The international application WO 2005/014626 relates to several strains of hMPV, designated by the following denominations: CAN 97-83, CAN 98-75 and HMPV 00-1. This application describes a strain of recombinant hMPV, designated CAN 97-83, genetically modified to attenuate its virulence. The modifications proposed notably relate to the total deletion of the genes encoding for the G and/or SH proteins. The modified virus strains may be used in human therapy, for preventing or treating infections with pneumoviruses. The administration of the wild strain or of these attenuated strains to hamsters makes it possible to protect them against later infection by a CAN 97-83 hMPV. However, WO 2005/014626 makes no mention of complete protective properties, in particular no weight monitoring of the treated animals is carried out. The same experimental results are described in the scientific articles cited in table 2.
With the same attenuated strains, in vivo results were next obtained on a monkey animal model; the recombinant virus strains deleted of SH, G and M2-2 genes continue to replicate in the respiratory tracts of the monkeys; and furthermore induce the production of neutralising antibodies just like the CAN97-83 wild virus strain.
Other isolated hMPV strains have been described in the U.S. Pat. No. 8,841,433, the use thereof for the preparation of vaccines also being proposed.
Vaccines based on the use of attenuated living virus strains have numerous advantages.
On the one hand, vaccines produced from attenuated living viruses have the advantage of inducing a strong immune response from a virus of which the capacity to multiply is considerably reduced, thus making it possible to avoid the occurrence of the pathology while mimicking the natural infection. During the development of these attenuated strains, it is important to find the ideal balance between attenuation and immunogenicity.
On the other hand, these vaccines may be administered by intra-nasal route, and thus mimic the natural entry route of wild viruses, thus inducing an immune response quite similar to the physiological response to an infection.
In addition, this vaccination strategy does not generate an exaggerated inflammatory reaction, as may be the case with inactivated vaccines. Finally, the addition of adjuvant is generally not necessary.
It is thus the optimal vaccinal strategy for prevention in populations at risk such as young children and infants.
The subject-matter of the invention is an attenuated virus strain derived from a particular clinical strain rC-85473 of human metapneumovirus, comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO.1 attenuating the virulence of said strain.
The attenuated virus strains according to the invention are notably recombinant strains modified by inactivation or deletion of at least one gene encoding for one of the G and SH accessory proteins, to generate recombinant viruses designated ΔG rC-85473 and ΔSH rC-85473, respectively.
More specifically, the subject-matter of the present invention is an attenuated virus strain derived from a clinical strain of human metapneumovirus, comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising at least one genetic modification selected from: inactivation of the gene encoding for the accessory G protein, and inactivation of the gene encoding for the accessory SH protein.
These strains were characterised with respect to their infectivity and their viral replication in in vitro (LLC-MK2 cell line) and ex vivo (reconstituted human respiratory epitheliums, cultured at the air-liquid interface) cell models, as well as with respect to viral pathogenesis and their property of vaccinal protection in a murine infection model by hMPV.
The results presented in the experimental section highlight the specific properties of these virus strains ΔG rC-85473 and ΔSH rC-85473, in comparison with those of virus strains modified in a similar manner, also deleted of G or SH genes, but derived from another clinical strain of hMPV (CAN98-75).
The viruses ΔG or ΔSH rC-85473 have in particular:
This attenuated virus strain may be used in vivo, ex vivo and in vitro as an expression vector of at least one exogenous gene, in particular a gene encoding for a viral antigen and, above all, viral antigens derived from the human respiratory syncytial virus (hRSV) and in particular its F fusion protein.
The invention also relates to this attenuated virus strain for the use thereof as a medicine, and more particularly for preventing and/or treating infections by viruses of the Pneumoviridae family.
Finally, the invention also relates to a vaccine composition comprising, in a pharmaceutically acceptable vehicle, at least one attenuated virus strain such as defined above, and optionally an adjuvant.
** p<0.01 and ***, p<0.001 (Two-way ANOVA statistical tests).
Statistical tests: Two-way ANOVA tests to compare each virus with the “mock” condition. *, p<0.05, ** p<0.01 and ***, p<0.001.
21 days after immunisation, the mice were infected by intranasal instillation with a lethal dose (1×106 TCID50) of the wild virus rC-85473. Their weight was monitored daily for 14 days.
The “mock” non-immunised mice have only 50% survival; those immunised by the recombinant viruses rC-85473, ΔSH-rC-85473 or ΔG-rC-85473 have 100% survival.
Statistical tests: Two-way ANOVA to compare each virus with the mock condition. *, p<0.05, ** p<0.01 and ***, p<0.001.
Reconstituted human respiratory epitheliums (MucilAir® HAE, Epithelix) were infected with the recombinant viruses rC-85473, ΔSH-rC-85473 and ΔG-rC-85473 at a MOI of 0.1. After 5 days of infection, the quantity of several cytokines and chemokines is measured by the Luminex technique (BioPlex Pro kit assay, BioRad) from the basal medium of the infected epitheliums:
Statistical tests: One-way ANOVA to compare the viruses ΔSH-rC-85473 and ΔG-rC-85473 with the virus rC-85473. *, p<0.05, ** p<0.01 and ***, p<0.001.
Statistical tests: Two-way ANOVA to compare the viruses ΔSH-rC-85473 and ΔG-rC-85473 with the virus rC-85473. *, p<0.05 and ** p<0.01.
Statistical tests: One-way ANOVA to compare the viruses ΔSH-rC-85473 and ΔG-rC-85473 with the virus rC-85473. ** p<0.01 and ***, p<0.001.
1 and/or 5 days after infectious challenge by the virus WT rC-85473 such as described in
In
N=2 or 3 mice/group, respectively for the histopathological or secretion of cytokines/cell recruitment analyses.
Statistical tests: Two-way ANOVA to compare each group with each other *, p<0.05, ** p<0.01 and ***, p<0.001.
Human Metapneumovirus (hMPV) Virus Strains
hMPVs were identified in 2001 as forming part of the Pneumoviridae family.
The genomic organisation of the hMPV is analogous to the hRSV. It is sub-divided into several ORFs (Open Reading Frames) encoding for N, P, M, F, M2 (M2-1 and M2-2), SH, G and L proteins. The general genome structure is represented for the viruses rC-8543 and rCAN98-75 in
Member viruses of the Pneumoviridae family express at their surface three glycoproteins designated F, G and SH proteins.
The F fusion glycoprotein, highly conserved between the different hMPV sub-groups, is involved in the penetration of the virus into the target cells, and the formation of syncytium, that is to say large multi-nucleated cells derived from the fusion of individual cells following their infection by the virus. The F glycoprotein is also considered as being the major antigen of the viruses hRSV and hMPV, making it possible to induce the production of neutralising antibodies.
The G protein is a type II membrane protein, its C-terminal end being outside of the cell. This protein is non-essential for the assembly of the viral constituents, and for replication in vitro. For hRSV, it has been shown that the deletion of the gene encoding this protein attenuated the virulence of the strain during infection of the respiratory tracts of mice.
The SH protein is also a type II membrane protein, the function of which in the viral cycle is still unknown. In the case of hRSV, the deletion of the gene encoding for the SH protein generates a recombinant virus capable of reproducing in vitro, and the virulence of which is attenuated in the upper respiratory tract of mice, but not in the lower part of said tract.
Genetic analysis of clinical hMPV strains has made it possible to define two major groups (serotypes A and B) and four “minor” sub-groups (A1, A2, B1 and B2), mainly based on the variability of the sequence of surface binding (G) and fusion (F) glycoproteins. It was next shown that these groups could again be sub-divided into sub-lines such as A2a and A2b (Huck et al., 2006).
Among widely studied virus strains may be cited the strain NL 00-1, belonging to the serotype A1; the strain CAN 97-83 belonging to the serotype A2; and the strain CAN 98-75, belonging to the serotype B2.
The present invention is based on a virus strain of human metapneumovirus, designated rC-85473, isolated from a patient sample in Canada, notably referenced in the article (Hamelin et al., 2010).
The use of the F protein of this strain, in combination with the M protein, has been proposed as a vaccinal strategy (Aerts et al., 2015a).
The use of this virus strain rC-85473, inactivated by treatment with formalin, as inactivated living vaccine strain, has been described in the article (Palwithino et al., 2015). A heat inactivated version of the strain rC-85473 has also been tested (Hamelin et al., 2007).
More recently, the strong fusion capacities of this strain have been studied in detail, on the basis of the protein sequence of its F protein (Dubois et al., 2017).
The sequence of the F gene and the M gene of the strain rC-85473 are referenced in GenBank, respectively with the access numbers KM408076.1 and KM408077.1.
The complete genome sequence of this virus strain rC-85473, comprising 13394 nucleotides, is here disclosed for the first time: it is represented in the appended list of sequences, under the reference SEQ ID NO. 1.
Table 4 below shows the identity percentage of this strain rC-85473 with three other virus strains of human metapneumovirus: CAN 97-83, CAN 98-75 and NL 00-1.
With regard to the high sequence homology observed with the strain NL 00-1, it may be concluded that this strain rC-85473 is member of the sub-group A1.
The strain rC-85473 is characterised by considerable fusogenic capacities, enabling it to penetrate into target cells at a high frequency/a high degree of infection. This considerable fusogenic capacity of this strain makes it possible to generate particularly elongated syncytia.
Syncytia are giant multinucleated cells. The virus rC-85473 has a high capacity of inducing cell fusion in vitro, leading to the formation of these very elongated syncytia, constituted of a very large number of cell nuclei.
It has been shown that 5 amino acids of the HRA functional domain of the F protein, amino acids unique among the other known hMPV strains, are in part responsible for this hyperfusogenic phenotype (Aerts et al., 2015b; Dubois et al., 2017).
According to a preferred embodiment of the present invention, the peptide sequence of the F protein of the attenuated virus strain derived from the strain rC-85473 comprises these 5 amino acids of the HRA functional domain such as described in (Dubois et al., 2017).
According to a preferred embodiment of the present invention, the peptide sequence of the F protein of the attenuated virus strain derived from the strain rC-85473 is not modified, and is thus identical to the peptide sequence of the F protein of the strain rC-85473 such as described in (Dubois et al., 2017).
Reverse Genetics Technology
Reverse genetics technology makes it possible to create, from a nucleic acid sequence, DNA or RNA, and from appropriate host cells, a functional encapsidated virus.
The recombinant strain rC-85473 of human metapneumovirus was thus obtained from a clinical strain designated C-85473, isolated in a patient.
The first reverse genetics system applied to the hMPV was described in 2004 (Biachesi et al., 2004). This technology is also described in the article (Aerts et al., 2015b).
The principle of this technology, which enables the production of recombinant hMPVs, is based on the use of a hamster kidney cell line (BHK-21) modified to express constitutively the RNA polymerase of the T7 bacteriophage (BHK-T7 or BSR-T7/5 cells).
The genome elements are distributed in five plasmid elements: A plasmid encoding the antigenome of hMPV and 4 “satellite” plasmids, encoding for the viral proteins of the transcription machinery (L, P, N and M2-1).
After co-transfection of the antigenomic plasmid hMPV and the four “satellite” plasmids in these cells, an RNA strand corresponding to the viral genomic strand (negative RNA strand), is transcribed by the T7 polymerase from its promoter.
The four proteins involved in the viral transcription of hMPV are also expressed by the transfected host cells to constitute an active RNA-dependent RNA polymerase (RdRP) complex. This functional viral polymerase thus transcribes the genomic RNA into viral mRNA then replicates it into new molecules of viral genomic RNA, via the transcription of matrix strands.
The translation and the assembly of viral proteins with genomic RNA thus enable the budding of infectious hMPV particles from the cytoplasmic membrane of transfected BHK-T7 cells. Next, amplification of the recombinant viruses is enabled thanks to the addition in co-culture of LLC-MK2 cells (ATCC CCL-7), permissive to infection.
Thus, from a genome sequence of a particular virus strain, it is possible to produce recombinant viruses thanks to these modified cells, which are commercially available.
Attenuated Virus Strain Derived from the Strain rC-85473
The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.
In the present application, the terms “a virus” and “a virus strain” are used indiscriminately to designate a particular virus strain, such as identified previously.
In the sense of the invention, “derived strain” is taken to mean a recombinant virus strain obtained by the introduction of genetic modifications into the genome of a so-called “original strain” virus strain. The original strain is advantageously a wild strain, for example a clinical isolate.
The genetic modifications introduced into the original strain all have the object of attenuating the virulence of said original strain, and not of modifying the identity of its genome.
In particular, these genetic modifications only concern genes encoding for proteins non-essential for the replication of the virus, in other words “accessory proteins”, such as SH and G proteins. In this genetically modified attenuated strain, the peptide sequence of the F protein of the original strain rC-85473 is not modified, and thus has the same peptide sequence as the original strain.
The virulence of a virus strain corresponds to the degree of rapidity of multiplication of a virus in a given organism, thus to its invasion rate. “Attenuating the virulence” is thus taken to mean decreasing the invasion rate of a virus in an organism.
This attenuation may take the form of a decrease in the replication capacities of the virus strain, and/or a decrease in its capacity to infect target cells, and/or instead a decrease in the pathology induced by the viral infection of the organism.
Thus, “attenuated virus strain” is taken to mean, in the sense of the invention, a recombinant virus, the virulence of which is decreased compared to that of the original virus strain, that is to say less than that of the original virus strain.
To measure the virulence of a virus strain, in vitro, ex vivo or in vivo tests may be carried out, such as for example in vitro replicative capacity tests (measured by TCID50/ml titration or quantitative PCR), monitoring by microscopic observation of the evolution of in vitro and ex vivo cytopathic effects, or monitoring of the clinical signs of the pathology, pulmonary histopathological observation and measurement of pulmonary viral loads in an in vivo infection model.
To compare the physiological effects of a wild strain and an attenuated strain, it is also possible to measure/determine different physiological parameters modified at the level of the lung and/or other immune systems of a host organism of the virus.
As is described in examples 7, 8 and 9 of the present application, the following viral-induced effects may be evaluated to compare the physiological effects of attenuated virus strains, either compared with each other or with the wild virus strain:
These various measurements make it possible to know in a more precise manner the physiological effect of each virus strain, and to choose as a function of these characteristics which would be the most suited for developing an attenuated living virus vaccine.
Genetic Modifications Introduced into a Virus Strain to Obtain the Attenuation Thereof
The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.
“Genetic modifications attenuating the virulence of said strain” is taken to mean genetic modifications relative to genes encoding for proteins non-essential for the replication of the virus, well known to the person skilled in the art. Among these proteins, G and SH proteins, described above, are notably known.
In other words, the present application relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain having been genetically modified to attenuate its virulence, that is to say that the genetic mutations introduced have been introduced uniquely into genes encoding for proteins non-essential for the replication of the virus.
Various genetic modifications making it possible to attenuate the virulence of a virus strain are known to the person skilled in the art. These modifications may be introduced into the genome of the original strain rC-85473.
Genetic modifications designate, in the sense of the invention, all modifications of an original nucleotide sequence such as the deletion of one or more nucleotides, the addition of one or more nucleotides, and the replacement of one or more nucleotides. These modifications notably comprise all modifications making it possible to shift the genetic reading frame, or to introduce a stop codon into the middle of a coding sequence, or the deletion of all or part of one or more coding sequences.
Among genetic modifications intended to attenuate the virulence of a virus strain, genetic modifications are notably known making it possible to inactivate or even to delete one or more genes encoding for proteins non-essential for the replication of the virus in culture.
For example, attenuated virus strains of human metapneumovirus have been obtained by the inactivation, in particular by the deletion, of genes encoding for accessory SH, G and M2-2 proteins.
However, depending on the characteristics of the original virus strain from which the attenuated strains are derived, the functional characteristics of the attenuated virus strains could be very different, the virulence of the strains depending both on the original genome and on the genetic modifications made.
According to a first aspect of the invention, the attenuated virus strain according to the invention is characterised in that the modifications of the sequence SEQ ID NO.1 comprise the inactivation of the gene encoding for the SH protein.
More particularly, the attenuated virus strain according to the invention is characterised in that the genetic modification of sequence SEQ ID NO.1 attenuating the virulence of said strain consists in an inactivation of the gene encoding for the SH protein.
In the sense of the invention, the inactivation of a gene designates the fact that this gene is modified in such a way that the product of the gene is no longer expressed, or expressed in a non-active form, expressed in such a small amount that the activity of this protein is inexistent. This inactivation of a gene may be carried out by all techniques well known to the person skilled in the art.
In particular, the inactivation of a gene may be obtained by the introduction of a point mutation into the gene, by the partial or total deletion of the coding sequences of the gene, or instead by modification of the gene promoter. These different genetic modifications will be carried out according to any one of the molecular biology techniques well known to the person skilled in the art.
In the sense of the invention, “deletion of a gene” is taken to mean the removal from the genome of the virus strain of a significant part of the coding sequence of this gene, notably:
According to a preferred embodiment, in the attenuated virus strain according to the invention, the gene encoding for the SH protein is totally deleted, that is to say that all (100% of) the coding sequence for the SH protein has been removed from the original sequence SEQ ID NO. 1.
In particular, said virus strain comprises the nucleotide sequence such as represented in SEQ ID NO. 2. More specifically, the sequence of said virus strain consists of the nucleotide sequence such as represented in SEQ ID NO. 2.
As is illustrated in the examples, this attenuated strain designated ΔSH-rC-85473 has the following characteristics:
According to a second aspect of the invention, the attenuated virus strain according to the invention is characterised in that the modifications of sequence SEQ ID NO.1 comprise the inactivation of the gene encoding for the G protein.
More particularly, the attenuated virus strain according to the invention is characterised in that the genetic modification of sequence SEQ ID NO.1 attenuating the virulence of said strain consists in an inactivation of the gene encoding for the G protein.
According to a preferred embodiment, in the attenuated virus strain according to the invention, the gene encoding for the G protein is totally deleted, that is to say that all (100% of) the coding sequence for the G protein has been removed from the original sequence SEQ ID NO. 1.
In particular, said virus strain comprises the nucleotide sequence such as represented in SEQ ID NO. 3. More specifically, the sequence of said virus strain consists of the nucleotide sequence such as represented in SEQ ID NO. 3.
As is illustrated in the examples, this attenuated strain designated ΔG-rC-85473 has the following characteristics:
According to a third aspect of the invention, the attenuated virus strain according to the invention is characterised in that the modifications of sequence SEQ ID NO.1 comprise the inactivation of two genes encoding for the G protein and the SH protein.
More particularly, the attenuated virus strain according to the invention is characterised in that the genetic modifications of sequence SEQ ID NO.1 attenuating the virulence of said strain consist in an inactivation of the two genes encoding one for the SH protein and the other for the G protein.
According to a particular embodiment, the inactivation of the two genes corresponds to the complete deletion of one or the other or of the two genes encoding for the G and SH proteins.
In addition, it is understood that any other genetic modification making it possible to attenuate the virulence of the strain rC-85437 could be introduced into the genome of said strain, represented by sequence SEQ ID NO.1.
Introduction of Exogenous Genes into the Genome of the Virus Strain rC-85473
According to an aspect of the invention, the nucleotide sequence of the attenuated virus strain according to the invention could be genetically modified by the introduction of at least one exogenous gene.
Thus, the attenuated virus strain according to the invention has a genome sequence that comprises at least one exogenous gene. This exogenous gene could in particular be a gene encoding for a viral antigen.
In the sense of the invention, “viral antigen” is taken to mean a protein element or an element of another nature, expressed by a virus, which the immunological system of an individual recognises as foreign and which causes a response in said individual by the production of specific antibodies and/or the stimulation of a cell immune response.
Viral antigens could in particular be selected from antigens expressed by at least one influenza virus, or by at least one virus of the Pneumoviridae family, such as the hRSV, or by at least one virus of the Paramyxoviridae family, such as the parainfluenza virus.
More particularly, said viral antigen could be selected from all or part of the F protein of the hRSV, and all or part of the haemagluttinin of the influenza or parainfluenza virus.
This attenuated virus strain will make it possible, during its administration to a patient, to generate a multiple immune response, both against the viral antigen expressed and against hMPV.
Such a strain making it possible to obtain a combined immune response against several viruses, following a single administration, is very advantageous.
In addition, such an attenuated virus strain comprising at least one exogenous gene could be used in vivo, ex vivo or in vitro, as expression vector of at least one exogenous gene in target cells of the human metapneumovirus.
‘Target cells of the human metapneumovirus’ designates the epithelial cells of the respiratory tract of individuals liable to be infected by this virus. This expression also designates all the cell lines enabling the in vitro replication of said virus.
Attenuated Virus Strain for the Use Thereof as a Medicine
The present invention also relates to an attenuated virus strain such as defined above, for the use thereof as a medicine.
Indeed, this strain may be used, notably, for treating or preventing viral infections.
The term “treat” designates the fact of combatting infection by a virus in a human or animal organism. Thanks to the administration of at least one composition according to the invention, the level of viral infection (infectious load) in the organism is going to decrease, and preferably the virus is going to disappear completely from the organism. The term “treat” also designates the fact of attenuating the symptoms associated with the viral infection (respiratory syndrome, renal failure, fever, etc.).
In the sense of the invention, the term “prevent” designates the fact of avoiding, or at least decreasing the risk of occurrence of an infection in a human or animal organism. Thanks to the administration of at least one attenuated virus strain according to the invention, the human or animal cells of said organism become less permissive to infection, and are thus best placed not to be infected by said virus.
More specifically, the invention relates to an attenuated virus strain such as defined above, for the use thereof for preventing and/or treating infections by viruses of the Pneumoviridae family.
It is understood that this attenuated virus strain will be preferably integrated in a vaccine composition comprising a pharmaceutically acceptable vehicle, suitable for suspending said strain and for the administration thereof.
Said vaccine composition comprises at least one attenuated virus strain according to the invention, making it possible to stimulate in a specific manner the immune system of a human or animal organism.
Thus, this vaccine composition comprises at least one attenuated living virus strain which plays the role of antigen, that is to say of compound inducing a specific immune response in the organism, which will retain the memory thereof.
Such a vaccine composition could be used as a preventive vaccine, that is to say intended to stimulate a specific immune response before infection of an organism by a pathogenic virus.
Such a vaccine composition could also be used as a therapeutic vaccine, that is to say intended to stimulate a specific immune response concomitantly with infection of an organism by said pathogenic virus.
The present invention also relates to a method for preventing and/or treating infections by Pneumoviridae in humans, comprising the administration, to individuals liable to be infected by such viruses, of at least one attenuated virus strain such as described previously.
The present invention also relates to a method for preventing and/or treating infections by Pneumoviridae in humans, comprising the administration, to individuals liable to be infected by such viruses, of at least one vaccine composition comprising at least one attenuated virus strain such as described previously.
According to a specific embodiment of the invention, the infections are infections by human metapneumoviruses.
According to another specific embodiment of the invention, the infections are infections by orthopneumoviruses, such as the human syncytial respiratory virus (hRSV).
The invention also relates to an attenuated virus strain, the sequence of which comprises at least one exogenous gene encoding for a viral antigen, for the use thereof for preventing and/or treating infections by viruses in which at least one viral antigen is expressed by said attenuated virus strain.
According to a particular embodiment, an attenuated virus strain according to the invention comprising, as exogenous viral antigen, the F protein of a hRSV, could be used for preventing and/or treating infections by a hRSV.
According to another particular embodiment, an attenuated virus strain according to the invention comprising, as exogenous viral antigen, the haemagluttinin of an influenza virus, could be used for preventing and/or treating infections by an influenza virus.
Pharmaceutical Composition Comprising at Least One Attenuated Virus Strain
The present invention also relates to a vaccine composition comprising, in a pharmaceutically acceptable vehicle, at least one attenuated virus strain according to the invention, and optionally an adjuvant.
According to the invention, the term “pharmaceutically acceptable vehicle” designates vehicles or excipients, that is to say compounds not having specific action on the infection considered here. These vehicles or excipients are pharmaceutically acceptable, which signifies that they may be administered to an individual or to an animal without risk of significant deleterious effects or prohibitive undesirable effects.
It is understood that the vaccine composition according to the invention comprises at least one effective amount of the attenuated virus strain. “Effective amount” is taken to mean, in the sense of the invention, a quantity of attenuated virus strain sufficient to trigger an immune reaction in the organism to which it is administered.
The vaccine compositions used according to the present invention are suited for oral, sublingual, inhalation, sub-cutaneous, intramuscular or intravenous administration.
According to a particular embodiment of the invention, the vaccine composition according to the invention is characterised in that it is in a pharmaceutical form intended for administration by inhalation.
Inhalation designates absorption by the respiratory tracts. It is in particular a method for absorption of compounds for therapeutic purposes, of certain substances in the form of gas, micro-droplets or powders in suspension.
The administration of pharmaceutical or veterinary compositions by inhalation, that is to say by the nasal and/or buccal passageways, is well known to the person skilled in the art.
Two types of administration by inhalation are distinguished:
The pharmaceutical form considered here is thus advantageously selected from: a powder, an aqueous suspension of droplets or a pressurised solution.
The population of individuals to vaccinate is mainly a pediatric population, that is to say constituted of individuals less than 18 years old, and more specifically young children less than 5 years old, and infants. Indeed, viruses of the Pneumoviridae family mainly infect these individuals, who have a tendency to have less strong immunity than older individuals.
The invention also relates to a vaccine composition such as described above, for the use thereof for preventing and/or treating infections by viruses of the Pneumoviridae family
The genetic constructions represented in
The complete sequences of these genetic constructions are presented in SEQ ID NO. 4 (GFP rC-85473), SEQ ID NO.5 (GFP ΔSH-rC-85473), SEQ ID NO.6 (GFP ΔG-rC-85473) and SEQ ID NO. 8 (GFP rCAN98-75). The sequences of the virus strains derived from rCAN98-75 and coupled to GFP are not represented but are accessible to the person skilled in the art on the basis of the other genetic constructions presented.
As the photos of LLC-MK2 cells infected with a multiplicity of infection (MOI) of 0.01 show, the viruses being visible thanks to GFP, the following generated recombinant viruses: ΔSH-rCAN98-75, ΔG-rCAN98-75, ΔSH-rC-85473 and ΔG-rC-85473 are functional and replicative. The cells are observed by fluorescence microscopy at three days post-infection.
The photos suggest that the recombinant viruses rCAN98-75 seem less infectious and less replicative than the recombinant viruses rC-85473: the intensity of the fluorescence is lower, and the syncytia are of more reduced dimensions.
LLC-MK2 cells were infected separately, with a multiplicity of infection of 0.01, by the following recombinant viruses:
The cell supernatants were collected each day for 7 days, in triplicate, then their viral loads were evaluated in TCID50/ml. Two-way ANOVA statistical tests were carried out to compare each deleted recombinant virus (ΔSH and ΔG) with the wild recombinant virus.
The recombinant viruses rC-85473, ΔSH-rC-85473 and ΔG-rC-85473 have replicative and production capacities much better than those of the viruses rCAN98-75, ΔSH-rCAN98-75 and ΔG-rCAN98-75. The viruses ΔSH-rCAN98-75 and ΔG-rCAN98-75 are the least efficient, whereas the viruses ΔSH-rC-85473 and ΔG-rC-85473 have the best production capacities in culture on LLC-MK2 cells.
In the tables below are represented the average loads of the viral stocks produced and concentrated for each recombinant virus rCAN98-75, ΔSH-rCAN98-75 and ΔG-rCAN98-75 (tableau 5) and rC-85473, ΔSH-rC-85473 and ΔG-rC-85473 (table 6).
The viral loads are counted in “TCID50” units which represents the final viral dilution at which 50% of the cell tissue is destroyed by the infection, or shows visible cytopathic effects (50% Tissue Culture Infective Dose).
These viral loads confirm the preceding results, namely that the attenuated virus strains derived from C-85437 have satisfactory replication capacities, not diminished compared to those of the original strain.
BALB/c mice were infected by intranasal instillation with:
The two virus doses used are equivalent (the wild viruses produce equivalent effects in the mice after infection).
The weight and the survival of the mice was monitored daily for 14 days (weight average over 10 mice±SEM).
In addition, 5 days after the infection, 5 mice by group underwent euthanasia for a measurement of pulmonary infection viral loads in TCI D50.
Statistical tests were carried out (two-way ANOVA) to compare each virus with the mock condition. *p<0.05, ** p<0.01 and ***, p<0.001.
These results indicate that the recombinant viruses ΔSH-rC-85473 or ΔG-rC-85473 only induce very little weight loss; in fact these groups of mice behave like the non-infected group of mice.
Furthermore, the pulmonary viral loads (
The results are different with the recombinant viruses ΔSH-rCAN98-75 and ΔG-rCAN98-75: the virus ΔSH-rCAN98-75 induces a very great weight loss (
The immunisation and infectious challenge protocol is shown in
BALB/c mice were immunised by intranasal instillation with of the OptiMem culture medium (“mock” negative control) or 5×105 TCID50 of the recombinant viruses rC-85473, ΔSH-rC-85473 or ΔG-rC-85473.
21 days after immunisation, the mice were infected (infectious challenge) by intranasal instillation of a lethal dose (1×106 TCID50) of the wild virus rC-85473.
The weight and survival of the mice was monitored daily for 14 days (weight average over 10 mice±SEM,
The survival of the mice was monitored daily for 14 days post-challenge, for the mice of the different groups (mock with 50% survival and immunised by the recombinant viruses rC-85473, ΔSH-rC-85473 or ΔG-rC-85473, exhibiting 100% survival). The results are shown in
5 days after the infectious challenge (i.e. at day 26 post-immunisation), 4 mice of each group underwent euthanasia to measure their pulmonary infection viral loads in TCID50 (
Statistical tests: Two-way ANOVA to compare each virus with the mock condition. *p<0.05, ** p<0.01 and ***, p<0.001.
These results confirm that the recombinant viruses ΔSH-rC-85473 or ΔG-rC-85473 only induce very little weight loss (the groups of mice behave like the group of non-infected mice) and that, in these experimental conditions, protect 100% of the mice challenged by a lethal dose of wild virus rC-85473. This protection is also illustrated by the absence of detection of infectious virus and wild genome rC-85473 (nd) in the lungs at D+5 after challenge and a high micro-neutralisation load of the serums at D+21 after challenge (>160) of mice immunised beforehand by the recombinant viruses ΔSH-rC-85473 and ΔG-rC-85473.
Table 7 below shows the results of micro-neutralisation tests, carried out from serums taken from mice of the different groups at D+20 (1 day before the infectious challenge) and at D+42 (21 days after the infectious challenge).
After inactivation for 30 minutes at 56° C. and dilution of the serums, they were incubated with 100 TCID50 (that is to say 100 infectious units such as determined according to the TCDI50/ml) of virus rC-85473 or virus rCAN98-75 for 2 hours at 37° C. This mix was next applied to the LLC-MK2 cells for a determination of the neutralisation load.
The neutralising antibody load is determined by the greatest dilution of serum at which LLC-MK2 cells, incubated with the serum+virus mix, do not show cytopathic effects, that is to say are considered negative for infection (on the basis of tests carried out in duplicate).
The figures represent the dilution of the serums tested at which the specific antibody loads efficiently neutralise the viral infection (micro-neutralisation load).
A result of 5 or 10 is representative of a primary immune response (first encounter with the virus). A result greater than or equal to 160 is characteristic of a maximum immune response, and signifies that the organism had already encountered the virus previously and thus was immunised.
The virus strains derived from the original strain rC-85473 make it possible to obtain a satisfactory neutralising humoral response against hMPV C-85473 (serotype A) and at least against the virus CAN98-75 (serotype B), after prior immunisation by the attenuated strains.
LLC-MK2 cells were infected (t=0) with:
The cells were infected on ice, for 0.5, 1, 2 or 3 h in order to vary the time of binding the viruses to the cells, before being washed then incubated at 37° C. for 24 h.
The percentage of cells infected measured at 24 h post-infection is representative of the quantity of virus capable of binding to the cells within the allocated time (0.5, 1, 2 or 3 h).
The results indicate different capacities of binding to LLC-MK2 cells in culture (and thus infection capacities) for the recombinant viruses as a function of the origin of their genome CAN98-75 or C-85473.
The results show much better cell binding and cell infection capacity for the attenuated viruses ΔSH-rC-85473 and ΔG-rC-85473 (around 60% of infected cells) in comparison to those of the viruses ΔSH-rCAN98-75 (40%) and ΔG-rCAN98-75 (fewer than 20% of infected cells).
Reconstituted human respiratory epitheliums (MucilAir® HAE, Epithelix) and maintained in culture at the air-liquid interface according to the instructions of the supplier Epithelix, were used to carry out these ex vivo experiments.
The photos shown in
The results of quantification of viral genome in the epitheliums (
The results of quantification of viral genome at the surface of the apical pole of the epitheliums (
On the other hand, no genome of the virus ΔG-rC-85473 is detected, indicating the absence of viral progeny production. A hypothesis is that the virus ΔG-rC-85473 could have lost the capacity to bud at the surface of the cells infected in this complex and pluri-stratified ex vivo system.
These differences could be of a nature to further argue in favour of the inventive character of our invention, focusing on the different properties between recombinant viruses of different origins in terms of hMPV virus strain, for the protection of our attenuated living vaccine candidates ΔSH-rC-85473 and ΔG-rC-85473.
Reconstituted human respiratory epitheliums (MucilAir® HAE, Epithelix) maintained in culture at the air-liquid interface, according to the instructions of the supplier Epithelix, were used to carry out these ex vivo experiments.
The quantification of a selection of cytokines and chemokines secreted in the basal medium of the infected epitheliums reflects the induction of a cell response that differs as a function of the recombinant viruses rC-85473 evaluated (
a) the virus ΔG-rC-85473 induces the secretion of a significantly lower quantity of the different cytokines and chemokines tested, in comparison with the wild strain rC-85473, with the exception of the pro-inflammatory cytokine TNF-α. These results are consistent with those shown in
b) the virus ΔSH-rC-85473, even though its capacity for infection and replication in the reconstituted human respiratory epithelium model is increased compared to that of the wild recombinant virus rC-85473 (
The levels of secreted chemokines MCP-1, IP-10, RANTES, IL-8, G-CSF and pro-inflammatory cytokines IFN-γ and TNF-α seem to indicate that epithelial cells infected by this virus ΔSH-rC-85473 are able to recruit the T lymphocyte, monocyte/macrophage, eosinophil and/or neutrophil immune cells necessary for putting in place an innate immune response and adaptive response of the host.
In addition, the virus ΔSH-rC-85473 leads to the secretion of IL-7, a cytokine inducing the differentiation of inactive lymphocytes into active T and B lymphocytes, and FGF, a growth factor involved in the repair of organic tissues, in amounts similar to the wild virus rC-85473.
Thus, infection by the virus ΔSH-rC-85473 enables epithelial cells to put in place the primary defence response to the infection, while being associated with a more reduced inflammatory response of the host, in comparison with that induced by the wild virus.
These differences would thus be in favour of the use of recombinant viruses derived from the strain rC-85473 as attenuated living vaccine, and preferentially from the attenuated strain ΔSH-rC-85473.
An immortalised line of mice macrophages was used to evaluate the replication and induction capacity of pro-inflammatory cytokines by the recombinant viruses rC-85473, ΔSH-rC-85473 and ΔG-rC-85473.
Macrophages form part of the first cells of the immune system recruited on the site of infection (in the present case, the respiratory epithelium). Macrophages contribute to the inflammatory response, to the innate response and to the stimulation of the adaptive response of the host.
The macrophages were infected by the recombinant viruses rC-85473, ΔSH-rC-85473 or ΔG-rC-85473 and their cell supernatants were collected each day for 2 days. The results are shown in
a) the viral loads measured in FFU/ml demonstrate that the virus ΔSH-rC-85473 has a decreased replicative capacity on the macrophages, compared to the wild recombinant virus, whereas the virus ΔG-rC-85473 shows a viral replication similar to the wild virus (
b) the secretion of the pro-inflammatory cytokines TNF-α (
The virus ΔSH-rC-85473 leads to a cytokine profile significantly different from that of the wild virus rC-85473 with an earlier secretion peak after 1 day post-infection, in comparison with the wild virus which is associated with a secretion peak at 2 days post-infection, concerning these two cytokines.
The virus ΔG-rC-85473 induces the secretion of cytokine TNF-α at levels comparable to the wild virus, but does not induce the secretion of cytokine IL-1β during the 2 first days of infection.
These results demonstrate that the virus ΔSH-rC-85473 conserves the capacity to infect murine macrophages, and especially to lead to the secretion of pro-inflammatory cytokines, despite a modified kinetic.
The virus ΔG-rC-85473 efficiently infects murine macrophages, but induces more weakly the secretion of pro-inflammatory cytokines, as has been observed on the reconstituted human respiratory epithelium model.
BALB/c mice were infected by intranasal instillation with:
After 5 days of infection, 5 mice per group underwent euthanasia and their lungs taken for a histo-pathological analysis and a measurement of the inflammation scores resulting from infection (
Statistical tests were carried out (two-way ANOVA) to compare each condition with each other:*p<0.05, ** p<0.01 and ***, p<0.001.
Furthermore, at 5 days post-infection, 5 mice per group underwent euthanasia and their lungs taken for the absolute quantification of the CD4+, CD8+ lymphocyte, neutrophil and macrophage immune cells infiltrated into the pulmonary tissue following infection (
Statistical tests were carried out (one-way ANOVA) to compare the condition ΔSH-rC-85473 with the condition rC-85473: ** p<0.01.
Thus, it would seem that the virus ΔSH-rC-85473 leads to reduced pulmonary inflammation, in coherence with the attenuation of the pathology viral-induced in a murine model (
These different results (
The attenuated strain ΔSH-rC-85473 seems particularly promising for the development of an attenuated living vaccine, with regard to its properties from the point of view of (i) the secretion of inflammatory cytokines and chemokines by epithelial and macrophagic cells, (ii) the induction of pulmonary inflammation in vivo and (iii) the infiltration in vivo of immune cells into the infected organ. Indeed, infection of a host by this attenuated strain is associated both with an efficient primary immune response (equivalent to that observed with the wild virus) and with a reduced inflammatory response.
Following a viral infection, a complex inflammatory and immune response is put in place on the site of the infection thanks to the secretion of cytokines and chemokines by infected epithelial cells (see
BALB/c mice were immunised by intranasal instillation with OptiMem culture medium (“mock” negative control) or 5×105 TCID50 of the recombinant viruses rC-85473, ΔSH-C-85473 or ΔG-C-85473.
21 days after immunisation, the mice were infected (infectious challenge) by intranasal instillation of a lethal dose (1×106 TCID50) of the wild virus rC-85473. The immunisation and infectious challenge protocol is shown in
1 or 5 days after the infectious challenge (i.e. at days 22 or 26 post-immunisation respectively), 3 mice of each group underwent euthanasia to quantify a selection of cytokines and chemokines secreted in the pulmonary tissue: the results are shown in
After 5 days, all the cytokines/chemokines tested were in sharp decrease compared to the levels measured on day 1 post-challenge, which demonstrates a resorption of the cytokine and inflammatory response induced by the challenge.
These results suggest that immunisation by the attenuated viruses ΔG-C-85473, and more particularly ΔSH-C-85473, leads to the local putting in place of a cytokine response different to that induced by immunisation by the corresponding non-attenuated virus WT.
To evaluate the recruitment of immunity cells on the site of the infection, the amount of main populations of immune cells that infiltrate into the pulmonary tissue to combat against the infection was measured; the results are shown in
Thus, the recruitment of T lymphocytes (CD8+ cytotoxic and CD4+ helpers) and B lymphocytes is significantly increased following immunisation with the virus ΔSH-C-85473, compared to the group immunised by the virus WT rC-85473, and compared to the group immunised by the virus ΔG-C-85473 (significant difference uniquely for B lymphocytes,
The populations of recruited macrophages and neutrophils do not show significant differences between the different viruses tested (
The group of mice immunised by the virus ΔG-C-85473 shows a cell recruitment profile similar to that of the group immunised by the virus WT, which suggests that the virus ΔG-C-85473 is as efficient for the induction of immune response as a wild virus (WT). Conversely, when the mice were immunised beforehand with the virus ΔSH-C-85473, the adaptive immune response in response to the infectious challenge is more important, while remaining balanced, whereas the innate response does not seem to be affected, which suggests that the virus ΔSH-C-85473 would not induce a more efficient memory immune response.
Finally, 5 days after the challenge, 2 mice per group underwent euthanasia to measure the pulmonary inflammation scores resulting from the challenge of each immunised and “mock” non-immunised group; the results are shown in
As expected with the use of a lethal inoculum of virus WT rC-85473, which corresponds to 50% mortality of the population [see
The results of
Thus, the attenuated virus ΔSH-C-85473 could enable better pulmonary recruitment of immune cells, in quantity and in quality, in response to a secondary infection, and thus contribute to limiting physiopathology and pulmonary inflammation of the infected host. This more efficient response of the host could also reflect a better memory immune response against the hMPV virus.
In conclusion, this attenuated virus ΔSH-C-85473 has the following characteristics:
| Number | Date | Country | Kind |
|---|---|---|---|
| 1856801 | Jul 2018 | FR | national |
| 1902934 | Mar 2019 | FR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/FR2019/051759 | 7/12/2019 | WO |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2020/021180 | 1/30/2020 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 8841433 | Fouchier et al. | Sep 2014 | B2 |
| Number | Date | Country |
|---|---|---|
| 2005014626 | Feb 2005 | WO |
| 2007038862 | Apr 2007 | WO |
| Entry |
|---|
| Biacchesi, et al., Journal of Virolog vol. 78, Issue 23, Dec. 1, 2004, pp. 12877-12887 (Year: 2004). |
| Aerts L, et al., PLoS ONE 10(3): e0120283. https://doi.org/10.1371/journal.pone.0120283 (Year: 2015). |
| Barouch—Nature vol. 455 Oct. 2, 2008 doi:10.1038/nature07352 (Year: 2008). |
| Weisshaar et al. DNA and CELL Bio vol. 34, pp. 506-510 (Year: 2015). |
| Van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719-24. |
| Peret TC, Boivin G, Li Y, Couillard M, Humphrey C, Osterhaus AD, Erdman DD, Anderson LJ. Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis. Jun. 1, 2002;185(11):1660-3. |
| Mazur NI, Higgins D, Nunes MC, Melero JA, Langeduk AC, Horsley N, Buchnolz UJ, Openshaw PJ, MCLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. Jun. 15, 2018. pii: vol. 18 (10) :e295-e311. |
| Herfst S, de Graaf M, Schrauwen EJ, Sprang L, Hussain K, van den Hoogen BG, Osterhaus AD, Fouchier RA. Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters. J Gen Virol. Jul. 2008;89(Pt 7):1553-62. |
| Wei Y, Zhang Y, Cai H, Mirza AM, Iorio RM, Peeples ME, Niewiesk S, Li J. Roles of the putative integrin-binding motif of the human metapneumovirus fusion (f) protein in cell-cell fusion, viral infectivity, and pathogenesis. J Virol. Apr. 2014;88(8):4338-52. |
| Yu CM, Li RP, Chen X, Liu P, Zhao XD. Replication and pathogenicity of attenuated human metapneumovirus F mutants in severe combined immunodeficiency mice. Vaccine. Jan. 5, 2012;30(2):231-6. |
| Liu P, Shu Z, Qin X, Dou Y, Zhao Y, Zhao X. A live attenuated human metapneumovirus vaccine strain provides complete protection against homologous viral infection and cross-protection against heterologous viral infection in BALB/c mice. Clin Vaccine Immunol. Aug. 2013;20(8):1246-54. |
| Zhang Y, Wei Y, Zhang X, Cai H, Niewiesk S, Li J. Rational design of human metapneumovirus live attenuated vaccine candidates by inhibiting viral mRNA cap methyltransferase. J Virol. Oct. 2014;88(19):11411-29. |
| Biacchesi S, Skiadopoulos MH, Tran KC, Murphy BR, Collins PL, Buchholz UJ. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology. 2004;321(2):247-59. |
| Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, Collins PL, Buchholz UJ. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. Journal of Virology. Dec. 2004;78(23):12877-87. |
| Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. Journal of virology. 2005;79(19):12608-13. |
| Buchholz UJ, Biacchesi S, Pham QN, Tran KC, Yang L, Luongo CL, Skiadopoulos MH, Murphy BR, Collins PL. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol. Jun. 2005;79(11):6588-97. |
| Schickli JH, Kaur J, Macphail M, Guzzetta JM, Spaete RR, Tang RS. Deletion of human metapneumovirus M2-2 increases mutation frequency and attenuates growth in hamsters. Virol J. Jun. 3, 2008;5:69. |
| Pham QN, Biacchesi S, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol. Dec. 2005;79(24):15114-22. |
| Tang RS, Schickli JH, MacPhail M, Fernandes F, Bicha L, Spaete J, Fouchier RA, Osterhaus AD, Spaete R, Haller AA. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol. Oct. 2003;77(20):10819-28. |
| Tang RS, Mahmood K, Macphail M, Guzzetta JM, Haller AA, Liu H, Kaur J, Lawlor HA, Stillman EA, Schickli JH, Fouchier RA, Osterhaus AD, Spaete RR. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus(hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine. Feb. 25, 2005;23(14):1657-67. |
| Russell CJ, Jones BG, Sealy RE, Surman SL, Mason JN, Hayden RT, Tripp RA, Takimoto T, Hurwitz JL. A Sendai Virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge. Virology. Sep. 2017;509:60-66. |
| Huck B, Scharf G, Neumann-Haefelin D, Puppe W, Weigl J, Falcone V. Novel human metapneumovirus sublineage. Emerg Infect Dis Jan. 2006;12(1):147-50. |
| Aerts L, Rhéaume C, Carbonneau J, Lavigne S, Couture C, Hamelin MÈBoivin G. Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines. J Gen Virol. Apr. 2015;96(Pt 4):767-74. |
| Dubois J, Cavanagh MH, Terrier O, Hamelin ME, Lina B, Shi R, et al. Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia. The Journal of general virology. 2017;98(6):1174-80. |
| Aerts L, Cavanagh MH, Dubois J, Carbonneau J, Rheaume C, Lavigne S, et al. Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model PloS one. 2015;10(3):e0120283. |
| Hamelin ME, Gagnon C, Prince GA Kiener P, Suzich J, Ulbrandt N, Boivin G. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res. Oct. 2010;88(1):31-7. |
| Palavecino CE, Cespedes PF, Lay MK, Riedel CA, Kalergis AM, Bueno SM. Understanding Lung Immunopathology Caused by the Human Metapneumovirus: Implications for Rational Vaccine Design. Crit Rev Immunol. 2015;35(3):185-202. Review. |
| Hamelin ME, Couture C, Sackett MK, Boivin G. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol. Dec. 2007;88(Pt 12):3391-400.PubMed PMID: 18024909. |
| Number | Date | Country | |
|---|---|---|---|
| 20210283239 A1 | Sep 2021 | US |
